Ipsen and Syntaxin have entered into global strategic collaboration for the discovery and development of new compounds in the field of botulinum toxins.  Syntaxin will be responsible for the discovery of new therapeutic candidates and Ipsen will apply its pharmacological, preclinical and clinical assessments of the discovered compounds. Syntaxin is eligible to receive a technology access fee, employee support, and research milestones totaling $9 million in the first three years of the collabora...